1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cell-Free DNA (cfDNA) Testing Market Size Growth Rate by Type: 2018 VS 2022 VS 2032
1.2.2 Donor-Derived Cell-Free DNA (DdcfDNA)
1.2.3 Circulating Cell-Free Tumor DNA (CtDNA)
1.2.4 Cell-Free Fetal DNA (NIPT)
1.3 Market by Application
1.3.1 Global Cell-Free DNA (cfDNA) Testing Market Share by Application: 2018 VS 2022 VS 2032
1.3.2 Hospital
1.3.3 Ambulatory Surgical Centers
1.3.4 Cancer Research Institutes
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Cell-Free DNA (cfDNA) Testing Market Perspective (2018-2032)
2.2 Cell-Free DNA (cfDNA) Testing Growth Trends by Region
2.2.1 Cell-Free DNA (cfDNA) Testing Market Size by Region: 2018 VS 2022 VS 2032
2.2.2 Cell-Free DNA (cfDNA) Testing Historic Market Size by Region (2018-2023)
2.2.3 Cell-Free DNA (cfDNA) Testing Forecasted Market Size by Region (2023-2032)
2.3 Cell-Free DNA (cfDNA) Testing Market Dynamics
2.3.1 Cell-Free DNA (cfDNA) Testing Industry Trends
2.3.2 Cell-Free DNA (cfDNA) Testing Market Drivers
2.3.3 Cell-Free DNA (cfDNA) Testing Market Challenges
2.3.4 Cell-Free DNA (cfDNA) Testing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cell-Free DNA (cfDNA) Testing Players by Revenue
3.1.1 Global Top Cell-Free DNA (cfDNA) Testing Players by Revenue (2018-2023)
3.1.2 Global Cell-Free DNA (cfDNA) Testing Revenue Market Share by Players (2018-2023)
3.2 Global Cell-Free DNA (cfDNA) Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cell-Free DNA (cfDNA) Testing Revenue
3.4 Global Cell-Free DNA (cfDNA) Testing Market Concentration Ratio
3.4.1 Global Cell-Free DNA (cfDNA) Testing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cell-Free DNA (cfDNA) Testing Revenue in 2022
3.5 Cell-Free DNA (cfDNA) Testing Key Players Head office and Area Served
3.6 Key Players Cell-Free DNA (cfDNA) Testing Product Solution and Service
3.7 Date of Enter into Cell-Free DNA (cfDNA) Testing Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cell-Free DNA (cfDNA) Testing Breakdown Data by Type
4.1 Global Cell-Free DNA (cfDNA) Testing Historic Market Size by Type (2018-2023)
4.2 Global Cell-Free DNA (cfDNA) Testing Forecasted Market Size by Type (2023-2032)
5 Cell-Free DNA (cfDNA) Testing Breakdown Data by Application
5.1 Global Cell-Free DNA (cfDNA) Testing Historic Market Size by Application (2018-2023)
5.2 Global Cell-Free DNA (cfDNA) Testing Forecasted Market Size by Application (2023-2032)
6 North America
6.1 North America Cell-Free DNA (cfDNA) Testing Market Size (2018-2032)
6.2 North America Cell-Free DNA (cfDNA) Testing Market Size by Country (2018-2023)
6.3 North America Cell-Free DNA (cfDNA) Testing Market Size by Country (2023-2032)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Cell-Free DNA (cfDNA) Testing Market Size (2018-2032)
7.2 Europe Cell-Free DNA (cfDNA) Testing Market Size by Country (2018-2023)
7.3 Europe Cell-Free DNA (cfDNA) Testing Market Size by Country (2023-2032)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cell-Free DNA (cfDNA) Testing Market Size (2018-2032)
8.2 Asia-Pacific Cell-Free DNA (cfDNA) Testing Market Size by Country (2018-2023)
8.3 Asia-Pacific Cell-Free DNA (cfDNA) Testing Market Size by Country (2023-2032)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Cell-Free DNA (cfDNA) Testing Market Size (2018-2032)
9.2 Latin America Cell-Free DNA (cfDNA) Testing Market Size by Country (2018-2023)
9.3 Latin America Cell-Free DNA (cfDNA) Testing Market Size by Country (2023-2032)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cell-Free DNA (cfDNA) Testing Market Size (2018-2032)
10.2 Middle East & Africa Cell-Free DNA (cfDNA) Testing Market Size by Country (2018-2023)
10.3 Middle East & Africa Cell-Free DNA (cfDNA) Testing Market Size by Country (2023-2032)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Agilent Technology
11.1.1 Agilent Technology Company Detail
11.1.2 Agilent Technology Business Overview
11.1.3 Agilent Technology Cell-Free DNA (cfDNA) Testing Introduction
11.1.4 Agilent Technology Revenue in Cell-Free DNA (cfDNA) Testing Business (2018-2023)
11.1.5 Agilent Technology Recent Development
11.2 Allenex
11.2.1 Allenex Company Detail
11.2.2 Allenex Business Overview
11.2.3 Allenex Cell-Free DNA (cfDNA) Testing Introduction
11.2.4 Allenex Revenue in Cell-Free DNA (cfDNA) Testing Business (2018-2023)
11.2.5 Allenex Recent Development
11.3 Biocept
11.3.1 Biocept Company Detail
11.3.2 Biocept Business Overview
11.3.3 Biocept Cell-Free DNA (cfDNA) Testing Introduction
11.3.4 Biocept Revenue in Cell-Free DNA (cfDNA) Testing Business (2018-2023)
11.3.5 Biocept Recent Development
11.4 Biodesix
11.4.1 Biodesix Company Detail
11.4.2 Biodesix Business Overview
11.4.3 Biodesix Cell-Free DNA (cfDNA) Testing Introduction
11.4.4 Biodesix Revenue in Cell-Free DNA (cfDNA) Testing Business (2018-2023)
11.4.5 Biodesix Recent Development
11.5 CareDx
11.5.1 CareDx Company Detail
11.5.2 CareDx Business Overview
11.5.3 CareDx Cell-Free DNA (cfDNA) Testing Introduction
11.5.4 CareDx Revenue in Cell-Free DNA (cfDNA) Testing Business (2018-2023)
11.5.5 CareDx Recent Development
11.6 Guardant Health
11.6.1 Guardant Health Company Detail
11.6.2 Guardant Health Business Overview
11.6.3 Guardant Health Cell-Free DNA (cfDNA) Testing Introduction
11.6.4 Guardant Health Revenue in Cell-Free DNA (cfDNA) Testing Business (2018-2023)
11.6.5 Guardant Health Recent Development
11.7 Illumania
11.7.1 Illumania Company Detail
11.7.2 Illumania Business Overview
11.7.3 Illumania Cell-Free DNA (cfDNA) Testing Introduction
11.7.4 Illumania Revenue in Cell-Free DNA (cfDNA) Testing Business (2018-2023)
11.7.5 Illumania Recent Development
11.8 Invited
11.8.1 Invited Company Detail
11.8.2 Invited Business Overview
11.8.3 Invited Cell-Free DNA (cfDNA) Testing Introduction
11.8.4 Invited Revenue in Cell-Free DNA (cfDNA) Testing Business (2018-2023)
11.8.5 Invited Recent Development
11.9 Natera
11.9.1 Natera Company Detail
11.9.2 Natera Business Overview
11.9.3 Natera Cell-Free DNA (cfDNA) Testing Introduction
11.9.4 Natera Revenue in Cell-Free DNA (cfDNA) Testing Business (2018-2023)
11.9.5 Natera Recent Development
11.10 Quest Diagnostics
11.10.1 Quest Diagnostics Company Detail
11.10.2 Quest Diagnostics Business Overview
11.10.3 Quest Diagnostics Cell-Free DNA (cfDNA) Testing Introduction
11.10.4 Quest Diagnostics Revenue in Cell-Free DNA (cfDNA) Testing Business (2018-2023)
11.10.5 Quest Diagnostics Recent Development
11.11 Roche Holdings
11.11.1 Roche Holdings Company Detail
11.11.2 Roche Holdings Business Overview
11.11.3 Roche Holdings Cell-Free DNA (cfDNA) Testing Introduction
11.11.4 Roche Holdings Revenue in Cell-Free DNA (cfDNA) Testing Business (2018-2023)
11.11.5 Roche Holdings Recent Development
11.12 Sequenom
11.12.1 Sequenom Company Detail
11.12.2 Sequenom Business Overview
11.12.3 Sequenom Cell-Free DNA (cfDNA) Testing Introduction
11.12.4 Sequenom Revenue in Cell-Free DNA (cfDNA) Testing Business (2018-2023)
11.12.5 Sequenom Recent Development
11.13 Trovagene
11.13.1 Trovagene Company Detail
11.13.2 Trovagene Business Overview
11.13.3 Trovagene Cell-Free DNA (cfDNA) Testing Introduction
11.13.4 Trovagene Revenue in Cell-Free DNA (cfDNA) Testing Business (2018-2023)
11.13.5 Trovagene Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
